Research progress of KRAS G12C inhibitors in the treatment of advanced colorectal cancer
10.3760/cma.j.cn371439-20250225-00091
- VernacularTitle:KRAS G12C抑制剂在晚期结直肠癌治疗中的研究进展
- Author:
Xin WU
1
;
Haipeng REN
Author Information
1. 潍坊市人民医院 山东第二医科大学第一附属医院肿瘤内科，潍坊 261000
- Keywords:
Colorectal neoplasms;
KRAS G12C inhibitors;
Molecular targete therapy
- From:
Journal of International Oncology
2025;52(8):538-542
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer (CRC) remains a leading cause of cancer mortality globally. Mutations of the KRAS gene occur in 30%-40% of metastatic colorectal cancer patients, contributing to resistance to anti-epidermal growth factor receptor therapy and poor prognosis. Targeted therapy for KRAS has always been a research hotspot. In recent years, KRAS G12C mutation inhibitors have achieved good efficacy in the treatment of solid tumors. KRAS G12C inhibitors can be used as monotherapies and in combination with other targeted inhibitors for metastatic KRAS G12C-mutant colorectal cancer. Analyzing the research progress of KRAS G12C inhibitors in CRC is of great significance and can provide reference for guiding the treatment of advanced CRC.
